Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
cuz nothing is out cuz nothing has happened?
These deals will be announced before any trials?
If they do announce financing from the PRV, what's the next move after that to bring it to ur expected 5 dollars?
I have the feeling the name change will be tomorrow.
I have the feeling the name change will be tomorrow.
I have the feeling the name change will be tomorrow.
From fda.gov, in order to apply for a PRV “relies on clinical data derived from studies examining a pediatric population and dosages of the drug intended for that population.” Does this not mean they need clinical trials first?
you know they don't have the PRV yet right?
those scores aren't impressive since CTYX is a perfect 300!
How is saying read the previous PR's anything of substance...???????????
I can find it through searching, and we are currently posting on it...?
not even going to reference an insider this time?
they only have the patent to deliver it through the eye
How many times do we have to tell you its non dilutive. They were all series A/C stocks that were authorized back in October and purchased in November. If you bother to read the articles of incorporation it says that the exchange rate of all series A is 35% of all outstanding shares and series C is 30%. They can print as many preferred series A/C shares as they want and it doesn't do any dilution because the conversion is bound to the number of common shares anyways.
I mean I'm sure since its a rare disease, and they already have a university partner, there is plenty of grant money to go around to run the phase 1 trial. The guy running the trial for the childhood cancer drug is one of the worlds top leading child neurosurgeons...
Grants? There's millions to go out to help solve cancer, Paul even showed on his linkedin a VC fund that was OVERFUNDED 300 million+ that was trying to help solve rabies and other rare diseases. He secured millions at nobelpharma, paul can do it AGAIN!
GUYS WE HAVE OUR FIRST UNIVERSITY PARTNER!!!!
"To help us develop this first in human approach we will be working with renown neurosurgeon Nick Boulis of Emory University."
LETS GO EMORY!!!!
Maybe they just wanted it to network tomorrow since it's rare disease day.
THE NEW SITE IS UP!!!!!!
https://curativebiotech.com
HYPE
https://curativebiotech.com/how-do-you-measure-a-year-in-a-life
BILLION DOLLAR MARKET CAP EOY
There's not that many drugs out there that are ready for clinical trials to treat rabies. (Last I looked there were 3, and IMT504 was the most mature)
Get well <3
Sure, that's what it should be at, but lots of shorts still floating because this ticker was dead a year ago. Get attention from other big pharma investors and this thing can balloon to 10 easily.
We going to 10 dollars on the MOASS after the name change!!!!!!!!!!!!!
Shorts have to cover on a name change? Can you link me something that verifies this? I haven't been able to verify this.
Why didnt they cash it out when literal sub pennies.
Why do you think/need there to be a short squeeze? This company if they get uplisted (or at least become fully reporting) + get funding should be worth a 1-2 billion dollars just off of speculation.
3-4 dollars eoy
Little trades make price go burr
Garr brought $SNCA to 2 dollars, he will bring $CURB to 2 dollars!!!!!!!!!!!!!!!!
bro, you've been saying that every week for basically the past month. the voices in your head are bound to be right at least once, let it be tomorrow.
$CURB LONG!
just bought 265k shares, I have absolutely no faith in this company but I am willing to ride out a updated registered domain address to dollarland
low volume shenanigans till news hits again
Why does it matter when a lot of the shares can't even be converted to common stock till may anyways?
because the next time to report since they were issued isn't until the end of the year report which isn't due yet?
We know there *is* funding, but we don't know the details
pretty weird since your criticism was that they don't report
Your response to me was that they were far away, now its the easiest thing in the world?
they hired the guy for the audit committee (probably with the shares), they meet most other requirements other than SEC reporting, which he's in charge of.
this company is worth 1billion when they get uplisted